Mario Boccadoro

发表

A retrospective real-life analysis of chronic myeloid leukemia patients in suboptimal response to imatinib: three centres experience.

Dario Ferrero, Elena Crisà, Giovanna Rege-Cambrin, 2012, SIES 2012.

CHROMOSOMAL ABNORMALITIES AND IMMUNOPHENOTYPE IN ELDERLY MULTIPLE MYELOMA PATIENTS AT DIAGNOSIS ENTERED IN A PROSPECTIVE RANDOMIZED TRIAL OF VELCADE-MELPHALAN-PREDNISONE AND THALIDOMIDE VS VELCADE-MELPHALAN-PREDNISONE

Mario Boccadoro, S Caltagirone, Marina Ruggeri, 2010 .

Data quality improvement of a multicenter clinical trial dataset

Gabriella Balestra, Gian Maria Zaccaria, Samanta Rosati, 2017, 2017 39th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC).

Early Relapse Risk in Patients with Newly Diagnosed Multiple Myeloma Characterized by Next-generation Sequencing

Gian Maria Zaccaria, Daniel Auclair, Mario Boccadoro, 2020, Clinical Cancer Research.

Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial.

Anthony Boral, Hartmut Goldschmidt, Mario Boccadoro, 2007, Blood.

AT7519, a Novel Small Molecule Multi-Cyclin Dependent Kinase Inhibitor, Induces Apoptosis in Multiple Myeloma VIA GSK3β

Kenneth C. Anderson, Nikhil C. Munshi, Mario Boccadoro, 2008 .

Cyclooxygenase-2 (COX-2) is frequently expressed in multiple myeloma and is an independent predictor of poor outcome.

Marina Ruggeri, Andreas Trojan, Federica Cavallo, 2005, Blood.

Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group

Kenneth C. Anderson, Benjamin Djulbegovic, Bart Barlogie, 2003, British journal of haematology.

HashClone: a new tool to quantify the minimal residual disease in B-cell lymphoma from deep sequencing data

Marco Beccuti, Francesca Cordero, Greta Romano, 2017, BMC Bioinformatics.

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma.

Hartmut Goldschmidt, Mario Boccadoro, David Irwin, 2005, The New England journal of medicine.

Biological and Clinical Relevance of miRNA Expression Signatures in Primary Plasma Cell Leukemia

Mario Boccadoro, Pierfrancesco Tassone, Laura Mosca, 2013, Clinical Cancer Research.

Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3.

Hartmut Goldschmidt, Meral Beksaç, Mario Boccadoro, 2011, Blood.

Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial

Vincenzo Callea, Mario Boccadoro, Sara Bringhen, 2006, The Lancet.

Thalidomide and lenalidomide: Mechanism-based potential drug combinations

Kenneth C. Anderson, Mario Boccadoro, M. Boccadoro, 2008, Leukemia & lymphoma.

Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN)

Gordon Cook, Monika Engelhardt, Hermann Einsele, 2020, Leukemia.